news roundup
CISCRP – in partnership with 10 leading pharmaceutical companies and clinical research service providers – has launched a new consortium that will focus energy and resources on community-based education to increase diverse representation in clinical trials.
Novotech and PPC Group, two Asia-Pacific CROs, majority owned by TPG Capital Asia, have formed a strategic partnership to what they say is the largest biotech specialist CRO platform in the Asia-Pacific. The two had already been collaborating over the last two years, but the partnership formally brings together staff, scale and synergies.
|
|
|
advertisement
Transforming Regulatory Affairs: Sharing Industry Peer Perspectives
December 10, 2019 at 11am EST
 Register Now
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
PPD has expanded its early development research services by adding neuroscience and ethno-bridging expertise at its clinical research units (CRUs). In Orlanda, FL, it has added a 52-bed CRU with multiple neurological indications, such as Alzheimer’s disease. which affects aging populations. PPD’s Las Vegas CRU, a hospital-adjacent, 24-bed unit, has expanded to include the conduct of Japanese ethno-bridging studies.
|
advertisement
Anti-Microbial Resistance and the Role of Vaccines
 On Demand
|
Articles
This article describes Clinical Research Malaysia’s, a research organization founded by Malaysia Ministry of Health, initiative to conduct GCP Refresher Workshop for clinicians, nurses, allied health professionals and study coordinators who have been certified with Malaysian GCP.
This article describes the need for the ALPHA Project, led by the Lupus Foundation of America, researchers at Tufts CSDD and a Global Advisory Committee of 13 lupus experts, to determine a clear course of action for the lupus community and its scientific advancement.
|
|
|
|
advertisement
Managing Signals in the Modern Pharmacovigilance Landscape
 On Demand
|
Blog Posts
In this Q&A, Dr. Riam Shammaa, Founder and CEO of INTELLiSTEM, discusses his novel stem cell discoveries, and how he plans to tackle clinical trial and therapy development challenges, and what the future development of cell-gene based cancer treatments look like.
Other functional areas have moved from Excel to more dynamic solutions, and pharmacovigilance is no exception. As this article author says, the decision organizations must make is how to implement the safety tracking system: with fit-for-purpose software-are-a-service or Excel.
| |
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
